# FDA Approves Generic Lacosamide from Aurobindo Pharma The U.S. Food and Drug Administration has approved Aurobindo Pharma Limited's generic lacosamide oral formulation, expanding the competitive landscape for this anti-epilepsy medication and potentially reducing treatment costs for patients. The approval is expected to increase price competition in the lacosamide market, benefiting healthcare systems and insurers while providing additional supply options for neurological disorder management.